Aspergillosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
[[Category:Fungal diseases]] | [[Category:Fungal diseases]] | ||
[[Category: | [[Category:Infectious disease]] | ||
[[de:Aspergillose]] | [[de:Aspergillose]] | ||
Revision as of 16:03, 26 January 2012
|
Aspergillosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Aspergillosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Aspergillosis medical therapy |
|
Risk calculators and risk factors for Aspergillosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Treatment
The drugs amphotericin B, caspofungin, flucytosine, itraconazole, voriconazole [1]
References
- ↑ Herbrecht R, Denning D, Patterson T, Bennett J, Greene R, Oestmann J, Kern W, Marr K, Ribaud P, Lortholary O, Sylvester R, Rubin R, Wingard J, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar P, Hodges M, Schlamm H, Troke P, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. (2002). "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis". N Engl J Med. 347 (6): 408–15. PMID 12167683. Unknown parameter
|month=ignored (help)
de:Aspergillose hr:Aspergiloza nl:Aspergillose uk:Аспергільоз } Template:WH Template:WS